EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

When Strong Recommendations Rest on Weak Evidence: Lessons From Therapeutic Apheresis Guidelines

Jeremy W Jacobs iD, Garrett S Booth iD, Brian D Adkins iD, Victoria Costa, Sheharyar Raza iD, Yara A Park iD, Joseph Yossi Schwartz, Evan M Bloch iD

Journal of Clinical Apheresis · 2026

DOI: 10.1002/jca.70098 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Apheresis, 2026. Verfasst von Jeremy W Jacobs und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Blood Component Removal, Practice Guidelines as Topic. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The American Society for Apheresis (ASFA) guidelines serve as a global standard for therapeutic apheresis practice. However, our analysis of the 2023 guidelines reveals discordance between the strength of recommendation and the quality of evidence. Among 166 indications, one‐third carry strong recommendations, yet only 8% are supported by high‐quality evidence. Over half (55%) are informed by low‐ or very‐low quality evidence. This mismatch is most pronounced for Category I indications, where apheresis is considered first‐line therapy: nearly one‐third are based on low‐quality data, yet 89% receive strong recommendations. Weak evidence is nine times more likely to prompt a strong recommendation for Category I versus Category III indications. This misalignment risks overutilization of apheresis, introduces ethical hurdles for clinical trials by diminishing equipoise, and may mislead patient expectations during informed consent. We advocate for greater transparency by stating the rationale underlying strong recommendations despite low‐quality evidence, acknowledgment of uncertainty where applicable, and suggested research to strengthen the evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood Component RemovalPractice Guidelines as TopicHumansEvidence-Based Medicine

Autor:innen und Institutionen

  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, USA.
  • Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Canadian Blood Services, Medical Affairs and Innovation, Toronto, Ontario, Canada.
  • Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.

ORCID-Profile: Jeremy W Jacobs, Garrett S Booth, Brian D Adkins, Sheharyar Raza, Yara A Park, Evan M Bloch

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Jacobs, J. W., Booth, G. S., Adkins, B. D., Costa, V., Raza, S., Park, Y. A., Schwartz, J. Y., & Bloch, E. M. (2026). When Strong Recommendations Rest on Weak Evidence: Lessons From Therapeutic Apheresis Guidelines. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70098

Vancouver

Jacobs JW, Booth GS, Adkins BD, Costa V, Raza S, Park YA, et al. When Strong Recommendations Rest on Weak Evidence: Lessons From Therapeutic Apheresis Guidelines. Journal of Clinical Apheresis. 2026. doi:10.1002/jca.70098

BibTeX
@article{Jacobs2026,
  author = {Jacobs, Jeremy W and Booth, Garrett S and Adkins, Brian D and Costa, Victoria and Raza, Sheharyar and Park, Yara A and Schwartz, Joseph Yossi and Bloch, Evan M},
  title = {When Strong Recommendations Rest on Weak Evidence: Lessons From Therapeutic Apheresis Guidelines},
  journal = {Journal of Clinical Apheresis},
  year = {2026},
  doi = {10.1002/jca.70098}
}
Kostenlos starten →